scholarly journals Sociodemographic and Smoking Behavioral Predictors Associated with Smoking Cessation According to Follow-up Periods: A Randomized, Double-blind, Placebo-controlled Trial of Transdermal Nicotine Patches

2007 ◽  
Vol 22 (6) ◽  
pp. 1065 ◽  
Author(s):  
Seung Kwon Myung ◽  
Hong Gwan Seo ◽  
Sohee Park ◽  
Yeol Kim ◽  
Dong Jin Kim ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Nicotine Patches ◽  
Transdermal Nicotine ◽  
Behavioral Predictors

Double-Blind, Placebo-Controlled Trial of Oral Immunotherapy (OIT) in Peanut (PN) Allergic Children: A Follow-up

2010 ◽  
Vol 125 (2) ◽  
pp. AB58 ◽  
Author(s):  
S.M. Jones ◽  
A.M. Scurlock ◽  
L. Pons ◽  
T.T. Perry ◽  
A.R. Morgan ◽  
...  
Keyword(s):  
Controlled Trial ◽  
Oral Immunotherapy ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals Effect of Metformin on Cigarette Withdrawal Syndrome and Abstinence in Lung Cancer Patients; A Double-blind Placebo-controlled Trial

2021 ◽  
Vol 14 (5) ◽  
Author(s):  
Bijan Pirnia ◽  
Raheleh Masoudi ◽  
Melika Sefidrood ◽  
Elham Zarghami ◽  
Kambiz Pirnia ◽  
...  
Keyword(s):  
Withdrawal Syndrome ◽  
Controlled Trial ◽  
Nicotine Withdrawal ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Urinary Cotinine ◽  
Metformin Group ◽  
Secondary Outcomes ◽  
Cigarette Withdrawal

Background: Lung cancer (LC) is a leading cause of cancer morbidity and mortality worldwide. One of the predisposing factors for LC is smoking. Metformin is the first line for diabetes treatment and is shown that it can be used for nicotine withdrawal syndrome reduction. Objectives: This study was conducted to evaluate the effects of metformin on reducing the nicotine withdrawal syndrome and increasing nicotine abstinence in patients with LC. Methods: In a randomized double-blind placebo-controlled trial from February 2018 to May 2019, 53 patients with LC were selected by respondent-driven sampling (RDS), and were assigned into two experimental and wait-list control (WLC) group through block randomization (BR). After 3 weeks of baseline assessment, metformin or placebo was prescribed in the form of escalating doses. Cigarette Withdrawal Scale (CWS-21), urinary cotinine levels, and exhaled carbon monoxide (eCO) levels were evaluated in 16 steps by the repeated measures. The primary outcomes include metformin efficacy on cigarette withdrawal syndrome and secondary outcomes include urinary cotinine levels and eCO level. The data were analyzed by generalized estimation equation (GEE), chi-square, and Atlas-Ti5. Results: The primary outcomes showed that the metformin group had significant effects on the improvement of depression, anxiety, craving, irritability, and appetite, difficulty in concentrating, appetite-weight, and insomnia during the 12-weeks treatment period (all P's < 0.05). In addition, only cravings scores remained constant until the 6-month follow-up (P < 0.05). Secondary outcomes demonstrated that urinary cotinine levels and eCO level significantly decreased in the metformin group (all P's < 0.05). However, this decrease did not remain constant at both levels until the 6-month follow-up (P > 0.05). Conclusions: Metformin had a clinical potential for reducing nicotine withdrawal. However, more studies are needed.

scholarly journals Randomized, Double-blind, Placebo-Controlled Trial of 2 Dosages of Sustained-Release Bupropion for Adolescent Smoking Cessation

2007 ◽  
Vol 161 (11) ◽  
pp. 1068 ◽  
Author(s):  
Myra L. Muramoto ◽  
Scott J. Leischow ◽  
Duane Sherrill ◽  
Eva Matthews ◽  
Louise J. Strayer
Keyword(s):  
Smoking Cessation ◽  
Sustained Release ◽  
Controlled Trial ◽  
Adolescent Smoking ◽  
Double Blind ◽  
Double Blind Placebo

Randomized, Controlled Trial of Transdermal Clonidine for Smoking Cessation

1993 ◽  
Vol 27 (9) ◽  
pp. 1025-1028 ◽  
Author(s):  
Daniel E. Hilleman ◽  
Syed M. Mohiuddin ◽  
Michael G. Delcore ◽  
B. Daniel Lucas
Keyword(s):  
Smoking Cessation ◽  
Behavior Modification ◽  
Potential Role ◽  
Controlled Trial ◽  
Care Facility ◽  
Double Blind ◽  
Cancer Society ◽  
Treatment Groups ◽  
Women Smokers

OBJECTIVE: To determine the efficacy and safety of clonidine versus placebo in smoking cessation. DESIGN: Single-center, randomized, double-blind, parallel-design comparison of transdermal clonidine with behavior modification, transdermal clonidine without behavior modification, placebo with behavior modification, and placebo without behavior modification. SETTING: Outpatient, university-based ambulatory care facility. PATIENTS: One hundred fifty generally healthy, highly nicotine-dependent cigarette smokers. INTERVENTION: Clonidine was given as the transdermal patch initiated 72 hours prior to smoking-cessation attempts and continued for six weeks thereafter. Clonidine was given at a dose of 0.2 mg/d for patients weighing more than 150 pounds (>67.5 kg) and at a dose of 0.1 mg/d for patients weighing less than 150 pounds (<67.5 kg). Behavior modification consisted of a total of 12 one-hour structured group training sessions. Patients not receiving behavior modification received printed material, which included the “Help Quit Kit” and the “I Quit Kit” from the American Cancer Society. MAIN OUTCOME MEASURES: Smoking-cessation rates were assessed at 6, 12, 24, and 52 weeks of follow-up. In addition, adverse reactions to clonidine or placebo were evaluated. RESULTS: Clonidine with behavior modification was statistically superior to the other three treatment groups but only at 6 weeks of follow-up. There were no differences in smoking-cessation rates among any of the treatment groups at any other follow-up intervals. Patients receiving behavior modification, regardless of whether they received clonidine, had better quit rates than patients not receiving behavior modification at all follow-up times except 52 weeks. Women receiving clonidine had significantly better quit rates than men receiving clonidine at all follow-up visits. Clonidine was associated with a significantly higher incidence of adverse effects than placebo (52 vs. 11 percent). However, the number of smokers withdrawing from the study was not greater with clonidine compared with placebo (9 vs. 7 percent, respectively). CONCLUSIONS: Clonidine is probably not effective as a pharmacologic adjunct to behavior modification in smoking cessation. It may have a potential role in women smokers who do-not respond to or cannot tolerate more traditional smoking-cessation therapies.

scholarly journals INTRACORONARY STEM CELL THERAPY AFTER MYOCARDIAL INFARCTION - TWELVE MONTHS FOLLOW-UP OF A RANDOMIZED, RIGOROUS DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

2010 ◽  
Vol 55 (10) ◽  
pp. A100.E938 ◽  
Author(s):  
Jochen Wöhrle ◽  
Nico Merkle ◽  
Volker Mailänder ◽  
Thorsten Nusser ◽  
Peter Schauwecker ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Stem Cell ◽  
Cell Therapy ◽  
Stem Cell Therapy ◽  
Controlled Trial ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document